Mirum Pharmaceuticals, Inc. Cash Flow Statement
MIRM / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
Mirum Pharmaceuticals, Inc. generated $56M in operating cash flow and $55M in free cash flow in FY2025. Free cash flow margin was 10.5% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.41 (distress zone, below 1.8 threshold)
- Negative profit margin: -26.1%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$23.4M | -$87.9M | -$163.4M | -$135.7M | -$84.0M | -$103.3M | -$52.6M | -$17.3M |
| Depreciation & Amortization | $24.2M | $23.6M | $10.8M | $3.2M | $595.0K | $305.0K | $139.0K | $0 |
| Operating Cash Flow | $55.8M | $10.3M | -$70.9M | -$120.1M | -$132.8M | -$89.1M | -$39.4M | -$373.0K |
| Capital Expenditures | $954.0K | $993.0K | $109.0K | $278.0K | $24.0K | $225.0K | $281.0K | $0 |
| Free Cash Flow | $54.9M | $9.3M | -$71.1M | -$120.4M | -$132.8M | -$89.3M | -$39.6M | -$373.0K |
| FCF Margin | 10.5% | 2.8% | -38.1% | -156.3% | -693.8% | - | - | - |